Jason Brown, MD
Hematology & Oncology · Ann Arbor, MINPI 1669855573
Payments from drug & device makers
Across 354 payments — averaging $6612.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$1.2M
- Pfizer$1M
- AbbVie$41K
- Janssen Research & Development, LLC$35K
- Merck$22K
- EMD Serono, Inc.$10K
- plus $17K from 27 others
Across 13 payments — averaging $727.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$8K
- Seagen Inc.$1K
What the payments were for
- Consulting fees$13,80939%
- Speaking & faculty fees$13,58638%
- Travel & lodging$2,8928%
- Food & beverage$5,07314%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 154 | $1,203,245 |
| Pfizer | 62 | $1,012,974 |
| AbbVie | 3 | $40,965 |
| Janssen Research & Development, LLC | 5 | $35,200 |
| Merck | 18 | $21,607 |
| EMD Serono, Inc. | 14 | $9,526 |
| Johnson & Johnson | 16 | $7,151 |
| AstraZeneca | 5 | $4,293 |
| Astellas Pharma US Inc | 3 | $2,234 |
| Janssen Scientific Affairs, LLC | 2 | $1,928 |
| Eisai Inc. | 18 | $403 |
| E.r. Squibb & Sons, L.L.C. | 10 | $179 |
| Novartis | 9 | $172 |
| Caris MPI, Inc. | 5 | $168 |
| Gilead | 1 | $108 |
| Sumitomo Pharma America, Inc. | 1 | $97 |
| Astrazeneca UK Limited | 1 | $88 |
| Astellas Pharma Europe Ltd | 2 | $79 |
| Bayer | 4 | $61 |
| Lilly USA, LLC | 3 | $51 |
| GSK | 2 | $45 |
| Sun Pharmaceutical Industries Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Averitas Pharma Inc. | 2 | $40 |
| Exelixis Inc. | 1 | $37 |
| Verity Pharmaceuticals Inc. | 2 | $33 |
| Genentech USA, Inc. | 1 | $27 |
| Teleflex LLC | 1 | $26 |
| Argenx US, Inc. | 1 | $19 |
| Foundation Medicine, Inc. | 1 | $18 |
| SK Life Science, Inc. | 1 | $17 |
| UCB, Inc. | 1 | $17 |
| Myovant Sciences Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,340,906 in reported general payments places this provider in the 95th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 31 | $811,767 |
| ErleadaApalutamide | 57 | $779,645 |
| OrgovyxRelugolix | 182 | $597,952 |
| Abiraterone Acetate | 213 | $384,907 |
| XtandiEnzalutamide | 17 | $270,558 |
| NubeqaDarolutamide | 19 | $224,070 |
| Ondansetron Hcl | 74 | $4,364 |
| Prednisone | 273 | $855 |
| Prochlorperazine Maleate | 72 | $715 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $531 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 15 | $440 |
| Gabapentin | 26 | $279 |
| Dexamethasone | 40 | $268 |
| Olanzapine | 52 | $240 |
| Oxycodone Hcl | 21 | $233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $37 | $811,76731 claims |
| Johnson & JohnsonErleada | $7,151 | $779,64557 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $97 | $597,952182 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,928 | $384,907213 claims |
| Astellas Pharma US IncXtandi | $2,234 | $270,55817 claims |
| BayerNubeqa | $61 | $224,07019 claims |
| Lilly USA, LLCOlanzapine | $51 | $24052 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Ann Arbor
- Assuntina SaccoAnn Arbor$8.1M
- Ibrahim SahinAnn Arbor$970K
- Garth StrohbehnAnn Arbor$290K
- Jonathan WeissAnn Arbor$177K
- Sreenivasa ChandanaGrand Rapids$19.1M
- Nehal LakhaniGrand Rapids$15M
- Hirva MamdaniDetroit$9.5M
- Jeffrey ZonderDetroit$8.2M
- Abhinav DeolDetroit$4.5M
- Harsh ShahDetroit$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.